Nuwellis Hires Mike McCormick as CEO

Nuwellis, a company focused on cardiorenal conditions, has appointed Mike McCormick as its new CEO, effective June 30. Current chairman, president, and CEO John Erb will transition from executive leadership and continue serving as chairman.

McCormick boasts over three decades of leadership experience covering product development, commercialization, corporate strategy, and value creation. He was a board member and independent director of Nuwellis from June 2023 through January 2026.

Throughout his career, McCormick has founded, scaled, and led both public and private medical technology companies.

Nuwellis develops solutions to support patient care through monitoring, therapy, and data-informed clinical decision-making in acute and chronic care settings. The company’s portfolio includes commercially available and development-stage technologies to address complex cardiorenal conditions.

The company was awarded a $3 million multi-year grant from the NIH in October to further develop its pediatric continuous renal replacement therapy (CRRT) device, Vivian.

Comments from Nuwellis

John Erb, departing CEO: “Mike brings an exceptional combination of operational leadership, commercial expertise, and strategic vision. His deep understanding of the medical device industry and proven track record of building and scaling innovative healthcare companies make him uniquely qualified to lead Nuwellis into its next phase of growth. I look forward to supporting Mike and the management team as Chairman of the Board.”

Mike McCormick, incoming CEO: “Nuwellis has an important opportunity to expand the role of precision fluid management in cardiorenal care. I am excited to work with our employees, leadership team, Board, clinicians, and customers to build on the Company’s momentum, strengthen commercial execution, advance our pipeline, and create value for patients, healthcare providers, and shareholders.”